RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07308106, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Participants with histologically or cytologically confirmed NSCLC.

    Inclusion criterion 2

  3. Toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1.

    Exclusion criterion 8

    Participants who have received systemic corticosteroid therapy with > 10 mg/day of prednisone or other immunosuppressive drugs within 2 weeks before the first dose of study treatment.

    Exclusion criterion 16

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose.

    Inclusion criterion 5

  5. Participants with other malignant tumors within 3 years prior to the first dose.

    Exclusion criterion 2

    Positive test for human immunodeficiency virus (HIV) or a medical history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.

    Exclusion criterion 12

  6. Pregnant or breastfeeding women.

    Exclusion criterion 18

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07308106, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form (ICF).
  • Participants with histologically or cytologically confirmed NSCLC.
  • Locally advanced or metastatic NSCLC with MET Abnormalities that has progressed after standard therapy.
  • At least one measurable lesion as assessed by the investigator according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose.
  • Life expectancy ≥ 3 months as assessed by the investigator.
  • Adequate organ and bone marrow function.
  • Male and female participants must agree to use highly effective methods of contraception during the study treatment period.
  • Participants must voluntarily join this study, sign the ICF, and be able to comply with the visits and related procedures specified in the protocol.

Exclusion Criteria:

  • Participants with known active central nervous system (CNS) metastasis, and/or carcinomatous meningitis, brainstem metastasis, metastases to spinal cord, or spinal cord compression.
  • Participants with other malignant tumors within 3 years prior to the first dose.
  • Presence of any of the following cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
  • Presence of severe and/or uncontrolled concomitant diseases.
  • Participants with a history of interstitial lung disease (ILD) or a history of non-infectious pneumonitis.
  • Clinically severe lung damage due to complications of lung disorder.
  • Risk of esophagotracheal fistula or esophagopleural fistula, or tumor invasion or compression of surrounding vital organs and blood vessels.
  • Toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1.
  • Known active pulmonary tuberculosis.
  • Known history of allogeneic organ transplant or allogeneic hematopoietic stem cell transplant.
  • Active hepatitis B and hepatitis C.
  • Positive test for human immunodeficiency virus (HIV) or a medical history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
  • Known allergy or hypersensitivity to SKB571 or its excipients; or a history of severe allergy to other monoclonal antibodies.
  • Participants who have undergone major surgery within 4 weeks before the first dose or are expected to require major surgery during the study.
  • Serious infection within 4 weeks before the first dose.
  • Participants who have received systemic corticosteroid therapy with > 10 mg/day of prednisone or other immunosuppressive drugs within 2 weeks before the first dose of study treatment.
  • Participants who have received a live vaccine within 30 days before the first dose, or plan to receive a live vaccine during the study.
  • Pregnant or breastfeeding women.
  • Have local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors.
  • Any condition that, in the investigator's opinion, interferes with the evaluation of study treatment, participant safety, or interpretation of study results, or any other condition that the investigator deems unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07308106, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07308106, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07308106